Salix To Present Data For Products Across Its Portfolio At The American College Of Gastroenterology 2020 Virtual Annual Meeting
Bausch Health Companies Inc. (NYSE/TSX: BHC) and its gastroenterology unit, Salix Pharmaceuticals, will present 11 scientific posters at the American College of Gastroenterology (ACG) 2020 Virtual Annual Scientific Meeting from October 23-28, 2020. These presentations highlight clinical data across Salix's portfolio, emphasizing their commitment to gastrointestinal health. Key topics include the efficacy of Rifaximin, Plecanatide, Methylnaltrexone, and NER1006. Robert Spurr, president of Salix, expressed enthusiasm for collaboration with healthcare professionals at this significant conference.
- None.
- None.
Eleven Scientific Posters to be Featured
LAVAL, QC, Oct. 22, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology (GI) business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, today announced 11 scientific posters presenting data that span Salix's portfolio at the American College of Gastroenterology (ACG) 2020 Virtual Annual Scientific Meeting, taking place Oct. 23-28, 2020.
"Salix continues to demonstrate its longstanding commitment to the GI community by presenting this broad collection of clinical data that span our portfolio at ACG. We look forward to participating in this premier GI conference and collaborating with scientists and health care professionals to continue to build on our deep knowledge and expertise in GI," said Robert Spurr, president, Salix.
The complete list of scientific posters that will be presented by Salix during ACG includes:
Rifaximin
- Frenette, Catherine. "Characterization of Stool Microbiota in Patients Treated with Rifaximin alone Versus Rifaximin Plus Lactulose for Reducing the Risk of Overt Hepatic Encephalopathy Recurrence."
- Frenette, Catherine. "Lack of Clinically Significant Changes in Colonic Microbial Antibiotic Susceptibility in Patients Treated with Rifaximin Alone Versus Rifaximin Plus Lactulose for Reducing the Risk of Overt Hepatic Encephalopathy."
Plecanatide
- Bharucha, Adil. "The Impact of Plecanatide on Abdominal Pain in Patients with Chronic Idiopathic Constipation and Irritable Bowel Syndrome with Constipation: Analysis from Four Phase 3 Studies."
- Brenner, Darren. "Efficacy of Plecanatide in Bloated Patients with Chronic Idiopathic Constipation and Moderate to Severely Bloated Patients with Irritable Bowel Syndrome with Constipation."
- Chang, Christopher. "Efficacy and Safety of Plecanatide in Patients with Chronic Idiopathic Constipation or Irritable Bowel Syndrome with Constipation: Intrinsic Factors Analyses from Four Studies."
- Moshiree, Baharak "Efficacy and Safety of Plecanatide in Patients with Chronic Idiopathic Constipation: Pooled Analyses of Two Phase 3 Trials Stratified by Concomitant Acid Suppression Use."
Methylnaltrexone
- Shah, Eric. "Subcutaneous Methylnaltrexone in Cancer and Noncancer Patients with Opioid Induced Constipation."
NER1006
- Cash, Brooks "A Pooled Safety Analyses of the 1 L Bowel Preparation NER1006 in Adults with Versus without Diabetes Mellitus: A Pooled Analyses of Two Randomized, Phase 3 Studies."
- Schoenfeld, Philip. "One Liter NER1006 is Efficacious as a Bowel Preparation for Colonoscopy in Patients with or without Diabetes Mellitus: A Pooled Analyses of Two Randomized, Phase 3 Studies."
- Sharma, Prateek. "NER1006 1 Liter Bowel Preparation Safety Profile in Patients with Mild or Moderate Renal Impairment: A Pooled Analyses of Two Phase 3 Trials."
Probiotic
- Harris, Lucinda. "An Open-Label, Multicenter Study to Assess the Efficacy and Safety of a Novel Probiotic Blend in Patients with Functional Gastrointestinal Disturbances."
About Salix
Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For more than 30 years, Salix has licensed, developed, and marketed innovative products to improve patients' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix is headquartered in Bridgewater, New Jersey. For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn.
About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.
Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in the Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
©2020 Salix Pharmaceuticals or its affiliates.
SAL.0168.USA.20
Investor Contact: Media Contacts: Arthur Shannon Lainie Keller (514) 856-3855 (908) 927-1198 (877) 281-6642 (toll free) Karen Paff (908) 927-1190
View original content to download multimedia:http://www.prnewswire.com/news-releases/salix-to-present-data-for-products-across-its-portfolio-at-the-american-college-of-gastroenterology-2020-virtual-annual-meeting-301157556.html
SOURCE Bausch Health Companies Inc.
FAQ
What will Bausch Health present at the ACG 2020 meeting?
When is the ACG 2020 Virtual Annual Scientific Meeting?
Who is the president of Salix Pharmaceuticals?
What is the stock symbol for Bausch Health?
What areas does Salix Pharmaceuticals focus on?
